Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

BGS649

Other · developed by Mereo BioPharma

Phase 2 Most advanced trial (none active)
MREO Developer
2 Registered trials

What is BGS649?

BGS649 is an investigational agent studied in endometriosis and obese hypogonadotropic hypogonadism.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Endocrine
Developer
Mereo BioPharma (MREO)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01200862 Phase 2 Obese Hypogonadotropic Hypogonadism Terminated MREO
NCT01190475 Phase 2 Endometriosis Completed MREO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

EndometriosisObese Hypogonadotropic Hypogonadism

More from Mereo BioPharma

Follow MREO, the company behind BGS649

See MREO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MREO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.